Skip Navigation LinksHome > June 2009 - Volume 123 - Issue 6 > Beta-Blocking Agent for Treatment ofInfantile Hemangioma
Plastic & Reconstructive Surgery:
doi: 10.1097/PRS.0b013e3181a3f435
Viewpoints

Beta-Blocking Agent for Treatment ofInfantile Hemangioma

Bigorre, Michele M.D.; Van Kien, Aurelie Khau M.D.; Valette, Huguette M.D.

Free Access
Article Outline
Collapse Box

Author Information

CHU Montpellier; Department of Orthopedic and Plastic Pediatric Surgery; Lapeyronie Hospital; Montpellier, France (Bigorre)

CHU Montpellier; Department of Vascular Medicine; Saint Eloi Hospital; Montpellier, France (Khau Van Kien)

CHU Montpellier; Pediatric Department; Arnaud de Villeuneuve Hospital; Montpellier, France (Valette)

Correspondence to Dr. Bigorre; CHU Montpellier; Department of Orthopedic and Plastic Pediatric Surgery; Lapeyronie Hospital; 371 Gaston Giraud Street; Montpellier 34295, France; mbigorre@gmail.com

Sir:

Figure. No caption a...
Image Tools

Infantile hemangioma is a benign vascular tumor that involutes spontaneously by 5 to 7 years of age. Approximately 10 percent of these tumors are problematic.

For function- and life-threatening hemangiomas, the first-line medical treatment is corticosteroid, followed by vincristine or interferon.1–3 Corticosteroid results in regression in 40 percent, stabilization in 30 percent, and no response in 30 percent of cases. Corticosteroid complications have been well described in the literature; all disappear after the treatment is stopped.4 The effect on blood pressure has not been studied. We report the effect of acebutolol (β-blocking agent), 10 mg/kg/day, in four infants with proliferating phase hemangioma.

The first patient had a parotid hemangioma diagnosed at 6 weeks of age. Initially, he was treated with corticosteroid (prednisolone, 2 mg/kg/day) and developed high blood pressure that necessitated acebutolol given at 10 mg/kg/day. The effect of this drug on the hemangioma was immediately visible; the color and bulk decreased. The corticosteroid was tapered progressively until the child was 5 months old. We attempted to stop acebutolol at 4 months but noticed that the hemangioma swelled each time we discontinued the drug. Acebutolol was maintained until the age of 1 year, when the hemangioma stabilized.

We treated two other 2-month-old patients with hemifacial hemangioma. One of these had ocular occlusion. Corticosteroid (prednisolone, 2 mg/kg/day) was given immediately. Because there was no response after 15 days of treatment, we began acebutolol at 10 mg/kg/day. The corticosteroid dosage was decreased slowly over 3 months and acebutolol was stopped at 1 year of age. The hemangioma regressed and the ocular occlusion improved during administration and after discontinuation of the corticosteroid (Fig. 1).

Fig. 1
Fig. 1
Image Tools

The fourth child was 13 months old and had a perineal hemangioma complicated by cutaneous ulcerations. We did not give corticosteroids; instead, acebutolol (10 mg/kg/day) was given, and we observed decreased vascularity and thickness and healing of cutaneous lesions over 1 month. He is always treated by acebutolol.

Acebutolol is a selective β-adrenergic receptor–blocking agent. We propose that it reduces blood flow to the hemangioma either by blocking the vasodilator response to β-adrenergic stimulation or by diminishing heart rate.

Acebutolol was administered to treat corticosteroid hypertension and induced an effectiveness on the proliferating phase hemangioma. The dose given was always minimal for hypertension. We had no complications during this treatment and no hypotension. The only contraindications were bronchial asthma and cardiac insufficiency. We plan a prospective clinical and Doppler sonographic study (corticosteroid versus acebutolol) to evaluate the possible effectiveness of acebutolol.

Michele Bigorre, M.D.

CHU Montpellier

Department of Orthopedic and Plastic Pediatric Surgery

Lapeyronie Hospital

Montpellier, France

Aurelie Khau Van Kien, M.D.

CHU Montpellier

Department of Vascular Medicine

Saint Eloi Hospital

Montpellier, France

Huguette Valette, M.D.

CHU Montpellier

Pediatric Department

Arnaud de Villeuneuve Hospital

Montpellier, France

Back to Top | Article Outline

REFERENCES

1. Boon LM, Bataille AC, Bernier V, Vermylen C, Verellen G. Medical treatment of juvenile hemangiomas (in French). Ann Chir Plast Esthet. 2006;51:310–320.

2. Enjolras O, Brevière GM, Roger G, et al. Vincristine treatment for function- and life-threatening infantile hemangioma (in French). Arch Pediatr. 2004;11:99–107.

3. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456–1463.

4. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg. 1999;104:1616–1623.

Back to Top | Article Outline
Section Description

GUIDELINES

Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:

* Text—maximum of 500 words (not including references)

* References—maximum of five

* Authors—no more than five

* Figures/Tables—no more than two figures and/or one table

Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS' enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.

We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.

The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.

Cited By:

This article has been cited 7 time(s).

Pediatric Annals
Infantile Hemangiomas: New Frontiers
Yan, AC
Pediatric Annals, 41(8): 318-319.
10.3928/00904481-20120727-07
CrossRef
International Journal of Pediatric Otorhinolaryngology
Propranolol therapy for infantile haemangiomas: Review of the literature
Zimmermann, AP; Wiegand, S; Werner, JA; Eivazi, B
International Journal of Pediatric Otorhinolaryngology, 74(4): 338-342.
10.1016/j.ijporl.2010.01.001
CrossRef
International Journal of Pediatric Otorhinolaryngology
Management of infantile subglottic hemangioma: Acebutolol or propranolol?
Blanchet, C; Nicollas, R; Bigorre, M; Amedro, P; Mondain, M
International Journal of Pediatric Otorhinolaryngology, 74(8): 959-961.
10.1016/j.ijporl.2010.05.013
CrossRef
Journal of Drugs in Dermatology
Current Treatments for Infantile Hemangiomas
Akhavan, A; Zippin, JH
Journal of Drugs in Dermatology, 9(2): 176-180.

Archives of Otolaryngology-Head & Neck Surgery
Propranolol in the Management of Airway Infantile Hemangiomas
Rosbe, KW; Suh, KY; Meyer, AK; Maguiness, SM; Frieden, I
Archives of Otolaryngology-Head & Neck Surgery, 136(7): 658-665.

Current Opinion in Otolaryngology & Head and Neck Surgery
Propranolol treatment for infantile hemangiomas
Buckmiller, LM
Current Opinion in Otolaryngology & Head and Neck Surgery, 17(6): 458-459.
10.1097/MOO.0b013e328332a4eb
PDF (277) | CrossRef
Plastic and Reconstructive Surgery
Propranolol as First-Line Treatment for Infantile Hemangiomas
Holmes, WJ; Mishra, A; Gorst, C; Liew, S
Plastic and Reconstructive Surgery, 125(1): 420-421.
10.1097/PRS.0b013e3181c2a731
PDF (2585) | CrossRef
Back to Top | Article Outline

©2009American Society of Plastic Surgeons

Login

Article Tools

Images

Share